Analyst Ratings For NASDAQ:AERI – Aerie Pharmaceuticals (NASDAQ:AERI)
Today, Mizuho reiterated its Buy rating on NASDAQ:AERI – Aerie Pharmaceuticals (NASDAQ:AERI) with a price target of $77.00.
Some recent analyst ratings include
- 6/1/2018-Mizuho Reiterated Rating of Buy.
- 3/5/2018-Seaport Global Securities Reiterated Rating of Buy.
- 10/23/2017-Guggenheim initiated coverage with a Buy rating.
- 10/16/2017-Needham & Company LLC Reiterated Rating of Buy ➝ Buy.
- On 5/29/2018 Casey C Kopczynski, Insider, sold 2,708 with an average share price of $50.15 per share and the total transaction amounting to $135,806.20.
- On 5/25/2018 Gerald D Cagle, Director, bought 1,000 with an average share price of $49.45 per share and the total transaction amounting to $49,450.00.
- On 5/21/2018 Gerald D Cagle, Director, bought 1,000 with an average share price of $50.25 per share and the total transaction amounting to $50,250.00.
- On 5/26/2017 Foresite Capital Fund Ii, L.P., Major Shareholder, sold 20,000 with an average share price of $55.95 per share and the total transaction amounting to $1,119,000.00.
- On 4/19/2017 Gerald D Cagle, Director, bought 2,000 with an average share price of $41.70 per share and the total transaction amounting to $83,400.00.
- On 2/15/2017 Geoffrey M Duyk, Director, sold 41,591 with an average share price of $46.63 per share and the total transaction amounting to $1,939,388.33.
- On 10/6/2016 Foresite Capital Fund Ii, L.P., Major Shareholder, sold 50,000 with an average share price of $40.34 per share and the total transaction amounting to $2,017,000.00.
Recent Trading Activity for NASDAQ:AERI – Aerie Pharmaceuticals (NASDAQ:AERI)
Shares of NASDAQ:AERI – Aerie Pharmaceuticals closed the previous trading session at 52.82 up +1.53 2.97% with 53.20000076293945 shares trading hands.